Technical analysis of Kalaris Therapeutics Inc (KLRS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Price Performance
| 1 month | -21.09% |
| 3 months | -32.63% |
| Year-to-date | -62.32% |
| 1 year | -28.38% |
| 3 years | -99.72% |
| 5 years | -99.97% |
52-Week Range
| 52-week High | $11.88 |
| 52-week Low | $3.03 |
| Avg Volume (90d) | 202K |
Technical Indicators
| SMA 50 | $3.96 |
| SMA 200 | $6.32 |
| Beta | 0.18 |
| 30-day Volatility (annualised) | 41.0% |
| Price vs SMA 50 | -19.8% |
| Price vs SMA 200 | -49.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.03 | |
| 2025-11 | $6.24 | +24.1% |
| 2025-12 | $8.44 | +35.3% |
| 2026-01 | $8.88 | +5.2% |
| 2026-02 | $10.46 | +17.8% |
| 2026-03 | $5.77 | -44.8% |
| 2026-04 | $5.52 | -4.3% |
| 2026-05 | $5.27 | -4.5% |
| 2026-06 | $4.07 | -22.8% |
| 2026-07 | $3.51 | -13.8% |
| 2026-08 | $4.04 | +15.1% |
| 2026-09 | $3.18 | -21.3% |
Price
| Price | $3.18 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.31 |
| EV / EBITDA | -0.96 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 10.98 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -0.21 |